MGX
What one share of Metagenomi Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are an in vivo genome editing company capitalizing on our proprietary technologies to create curative genetic medicines for patients. We were founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel gene editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome.
Metagenomi Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.49 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.29 |
| Cash and investments | $1.03 |
| Book value | $2.98 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $13.15 | −$20.05 | $2.88 | −$29.73 | — | −$39.82 |
| 2024 | $1.58 | −$2.36 | $0.09 | −$3.40 | — | $6.28 |
| 2025 | $0.68 | −$2.36 | $0.02 | −$2.40 | — | $4.22 |